Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for alcohol use disorder
TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE)– Clearmind Medicine Inc. (CSE: CMND, FSE:CWY0, OTC Pink: CMNDF)
(“Clearmind” or the “Company“), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announced that as part of its highly attended “Psychedelics for Alcoholism” event series it will host market analyst Marissa Wright at a virtual event for investors.
The online event will be held on February 23, 2022 at 12 p.m. EST and is open and free to all, Registration is required.
Clearmind’s last webinar attracted more than 1200 viewers.
“Psychedelics for Alcoholism: Investor Deep Dive” will provide investors a broad overview of the psychedelic treatments market with an emphasis on alcohol use disorders.
Wright is a consultant on business strategy, market analysis, and new market entry for global firms. Based in Vancouver, Canada, she has 40 years of experience as an entrepreneur across a wide range of industries in North America and is an active member of Keiretsu Forum, the world’s largest early-stage angel investor network.
“As an innovative public company with a significant IP portfolio operating in an exciting and relatively new market, we want to provide investors a comprehensive review of the psychedelic treatment market and its potential,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind “The problem of alcoholism is only getting worse, with increased strain from the pandemic. Clearmind is working to bring long overdue relief and a new treatment in unique ways, and we look forward to highlighting some of the major reasons for our decision to pursue alcoholism indication as our first indication.”
The event will be hosted by Shannon Smadella, formerMiss Canada & Spokesperson for World Psychedelics Day, and will feature Adi Zuloff-Shani, PhD, Chief ExecutiveOfficer of Clearmind and Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development.
To learn more about Psychedelics for Alcoholism, visit the event website.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and willremain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on theCanadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol“CWYO” and on the OTC pink under the symbol “CMNDF“.
For further information, please contact:
Email: firstname.lastname@example.org Telephone: (604) 260-1566
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful.The securities issued, or to be issued, under the PrivatePlacement have not been, and will not be, registered under the UnitedStates Securities Act of 1933, as amended, and may not be offered or sold in the UnitedStates absent registration or an applicable exemption from registration requirements.
Neither the Canadian SecuritiesExchange (the “CSE”) nor its RegulationServices Provider (as that term is defined in the policies of the CSE)accepts responsibility for the adequacy or accuracy of this release.